Stallion India Fluorochemicals Submits Draft Letter of Offer for Rights Issue
Stallion India Fluorochemicals Limited has submitted its Draft Letter of Offer for a proposed Rights Issue. The issue aims to raise up to ₹364.00 crores by issuing new equity shares at ₹[⦁] each to existing shareholders. The DLOF was filed with NSE and BSE on January 24, 2026. The exact dates for the issue opening and closing are yet to be announced.
A rights issue of this size (₹364.00 crores) can have a significant impact on the company's capital structure and future growth prospects. However, the impact is currently pending the finalization of terms and successful subscription.
The announcement is a procedural step regarding a proposed rights issue. While it indicates a capital-raising activity, it does not provide concrete details on the outcome or immediate financial impact, hence it is neutral.
Stallion India Fluorochemicals Limited has officially submitted the Draft Letter of Offer (DLOF) for its proposed Rights Issue. This submission was made to both the BSE Limited and the National Stock Exchange of India Limited on January 24, 2026, in compliance with SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The company was originally incorporated as Stallion India Fluorochemicals Private Limited in September 2002 and later converted to a Public Limited Company. Its equity shares were listed on the BSE and NSE on January 23, 2025.
The proposed Rights Issue aims to raise up to ₹364.00 crores through the issuance of fully paid-up equity shares of face value ₹10.00 each. The issue price is set at ₹[⦁] per equity share, including a premium of ₹[⦁] per equity share. This is being offered to existing equity shareholders in a ratio of [⦁] rights equity shares for every [⦁] fully paid-up equity shares held as of the record date, which is yet to be finalized ([⦁]).
The Draft Letter of Offer, dated January 23, 2026, details the terms of the issue, risk factors, financial information, and other relevant disclosures. The company has received 'in-principle' approvals from NSE and BSE for the Rights Equity Shares, with BSE Limited designated as the Stock Exchange for this issue. The issue programme, including opening and closing dates, is yet to be announced.
What to do with a filing like this
Stallion India Fluorochemicals Limited filed this with the NSE as a statutory disclosure, categorised under equity fundraising. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Stallion India Fluorochemicals Limited. Read the original for the full detail.